Tirzepatide

Head-to-head clinical trials have shown that Tirzepatide leads to greater weight loss and better blood sugar control than Semaglutide. This is attributed to its dual-action mechanism targeting both GIP and GLP-1 receptors, whereas Semaglutide only targets GLP-1. However, individual response and tolerance can vary.

Nausea is the most common side effect, especially when starting or increasing the dose. To manage it, stick to the slow titration schedule, eat smaller, bland meals, avoid high-fat foods, and stay well-hydrated. The nausea typically subsides as your body adjusts over a few weeks.

Any significant weight loss will involve some loss of lean muscle mass along with fat. To minimize this, it's critical to engage in regular resistance training and consume adequate protein (at least 1.2-1.6g per kg of body weight). Stacking with a GHS like Ipamorelin or Tesamorelin is also a strategy researchers use to help preserve muscle.

You may notice appetite suppression within the first week. Noticeable weight loss typically begins within the first 4 weeks on the 2.5mg or 5mg dose. The most significant results are seen at higher doses (10-15mg) over several months, as shown in the year-long clinical trials.

Tirzepatide manages the chronic conditions of obesity and diabetes; it doesn't cure them. Studies show that if you stop taking it, appetite and weight are likely to return. It's designed for long-term use, and any plan to discontinue should be made with a long-term diet and lifestyle strategy in place.